Arrowhead Pharmaceuticals, Inc. (ARWR)

Market Cap	2.33B
Revenue (ttm)	19.65M
Net Income (ttm)	-538.64M
Shares Out	124.32M
EPS (ttm)	-4.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	752,286
Open	18.56
Previous Close	18.60
Day's Range	18.04 - 18.75
52-Week Range	17.05 - 39.83
Beta	0.93
Analysts	Buy
Price Target	45.33 (+142.28%)
Earnings Date	Nov 26, 2024

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 16, 1993
• Employees: 525
• Stock Exchange: NASDAQ
• Ticker Symbol: ARWR
• Website: https://arrowheadpharma.com

Financial Performance

In 2023, Arrowhead Pharmaceuticals's revenue was $240.74 million, a decrease of -1.03% compared to the previous year's $243.23 million. Losses were -$205.28 million, 16.6% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $45.33, which is an increase of 142.28% from the latest price.

Price Target

$45.33

(142.28% upside)

Analyst Consensus: Buy